Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

25 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Brentuximab vedotin after autologous transplantation in pediatric patients with relapsed/refractory Hodgkin lymphoma.
Forlenza CJ, Rosenzweig J, Mauguen A, Buhtoiarov I, Cuglievan B, Dave H, Deyell RJ, Flerlage JE, Franklin AK, Krajewski J, Leger KJ, Marks LJ, Norris RE, Pacheco M, Willen F, Yan AP, Harker-Murray PD, Giulino-Roth L. Forlenza CJ, et al. Among authors: harker murray pd. Blood Adv. 2023 Jul 11;7(13):3225-3231. doi: 10.1182/bloodadvances.2022009323. Blood Adv. 2023. PMID: 36897253 Free PMC article.
Nivolumab and brentuximab vedotin with or without bendamustine for R/R Hodgkin lymphoma in children, adolescents, and young adults.
Harker-Murray P, Mauz-Körholz C, Leblanc T, Mascarin M, Michel G, Cooper S, Beishuizen A, Leger KJ, Amoroso L, Buffardi S, Rigaud C, Hoppe BS, Lisano J, Francis S, Sacchi M, Cole PD, Drachtman RA, Kelly KM, Daw S. Harker-Murray P, et al. Blood. 2023 Apr 27;141(17):2075-2084. doi: 10.1182/blood.2022017118. Blood. 2023. PMID: 36564047 Free PMC article. Clinical Trial.
Radiation Therapy Use in Refractory and Relapsed Adolescent and Young Adult Hodgkin Lymphoma: A Report from the Children's Oncology Group.
Mailhot Vega RB, Harker-Murray PD, Forlenza CJ, Cole P, Kelly KM, Milgrom SA, Parikh RR, Hodgson DC, Castellino SM, Kahn J, Roberts KB, Constine LS, Hoppe BS. Mailhot Vega RB, et al. Among authors: harker murray pd. Int J Radiat Oncol Biol Phys. 2023 Oct 1;117(2):400-403. doi: 10.1016/j.ijrobp.2023.04.022. Epub 2023 Apr 26. Int J Radiat Oncol Biol Phys. 2023. PMID: 37116589
Children's Oncology Group's 2023 blueprint for research: Hodgkin lymphoma.
Castellino SM, Giulino-Roth L, Harker-Murray P, Kahn JM, Forlenza C, Cho S, Hoppe B, Parsons SK, Kelly KM; COG Hodgkin Lymphoma Committee. Castellino SM, et al. Pediatr Blood Cancer. 2023 Sep;70 Suppl 6(Suppl 6):e30580. doi: 10.1002/pbc.30580. Epub 2023 Jul 28. Pediatr Blood Cancer. 2023. PMID: 37505794
MRD at the end of induction and EFS in T-cell lymphoblastic lymphoma: Children's Oncology Group trial AALL1231.
Hayashi RJ, Hermiston ML, Wood BL, Teachey DT, Devidas M, Chen Z, Annett RD, Asselin BL, August K, Cho S, Dunsmore KP, Freedman JL, Galardy PJ, Harker-Murray P, Horton TM, Jaju A, Lam A, Messinger YH, Miles RR, Okada M, Patel S, Schafer ES, Schechter T, Shimano KA, Singh N, Steele A, Sulis ML, Vargas SL, Winter SS, Wood C, Zweidler-McKay PA, Loh ML, Hunger SP, Raetz EA, Bollard CM, Allen CE. Hayashi RJ, et al. Blood. 2024 May 16;143(20):2053-2058. doi: 10.1182/blood.2023021184. Blood. 2024. PMID: 38457359 Clinical Trial.
Emerging immunotherapy in pediatric lymphoma.
Erker C, Harker-Murray P, Burke MJ. Erker C, et al. Future Oncol. 2016 Jan;12(2):257-70. doi: 10.2217/fon.15.282. Epub 2015 Nov 30. Future Oncol. 2016. PMID: 26616565 Review.
25 results